ASTH Stock Forecast & Price Target

Astrana Health is positioned to benefit from a value-based care model that aligns payer, physician, and patient incentives, with 100% of its 8 ACOs generating shared savings in PY 2024 and $120.4M in gross shared savings, while managing about 100,000 Medicare beneficiaries. Its payer-agnostic platform, 12k+ contracted physicians, and capital-light growth strategy support recurring revenue and scalable expansion, and its ability to shift more members into higher-risk arrangements should improve earnings as Medicare reimbursement rises in 2027. The outlook is also reinforced by improving operating leverage, including G&A margin declining from 7.1% in 1Q:25 to 6.4% in 1Q:26, alongside evidence that core medical trend was about 4%, indicating disciplined cost control and strong care coordination.

Astrana Health is facing a fragile fundamental setup because the reported 2025 pro forma revenue decline of 3.5% and just $1.2M of GAAP net income suggest thin earnings quality, while much of the apparent weakness reflects distressed Prospect operations rather than clean organic strength. Even if legacy revenue excluding Prospect grew 15% on a constant-entity basis in Q1 2026 and ACO REACH savings were solid at about 8.4% with a ~75% quality score, the business remains exposed to reimbursement pressure, regulatory change, and payer-dependent revenue concentration, with Medicaid estimated at ~24% of total revenue. The September 22 cybersecurity incident also highlights operational and governance risk, and the recently disclosed $545M affiliate loan with annual dividend coverage of roughly $26M versus about $54.5M of interest underscores balance-sheet and capital-allocation concerns.